Organon & Co. Sees Unusually Large Options Volume (NYSE:OGN)

Organon & Co. (NYSE:OGN) saw unusually large options trading activity on Tuesday. Investors bought 17,794 call options on the stock. This represents an increase of approximately 550% compared to the average volume of 2,737 call options.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Royal Bank of Canada lifted its stake in shares of Organon & Co. by 53.4% in the first quarter. Royal Bank of Canada now owns 360,862 shares of the company’s stock valued at $5,374,000 after buying an additional 125,648 shares during the period. Amundi raised its holdings in Organon & Co. by 16.7% in the 1st quarter. Amundi now owns 719,105 shares of the company’s stock valued at $10,392,000 after acquiring an additional 102,715 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Organon & Co. by 870.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 1,010,789 shares of the company’s stock worth $15,051,000 after acquiring an additional 906,675 shares during the period. Goldman Sachs Group Inc. grew its holdings in shares of Organon & Co. by 126.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,435,198 shares of the company’s stock worth $21,370,000 after purchasing an additional 801,307 shares in the last quarter. Finally, Fred Alger Management LLC acquired a new stake in shares of Organon & Co. during the 1st quarter worth approximately $267,000. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Stock Performance

Shares of NYSE OGN traded up $0.44 during trading hours on Tuesday, hitting $7.88. 1,710,009 shares of the company’s stock were exchanged, compared to its average volume of 3,513,408. The company’s 50-day moving average price is $7.17 and its 200-day moving average price is $8.87. Organon & Co. has a 1-year low of $6.18 and a 1-year high of $17.23. The stock has a market capitalization of $2.05 billion, a price-to-earnings ratio of 4.10, a PEG ratio of 1.50 and a beta of 0.58. The company has a debt-to-equity ratio of 9.69, a current ratio of 1.75 and a quick ratio of 1.20.

Organon & Co. (NYSE:OGN) last released its earnings results on Monday, November 10th. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.93 by $0.08. Organon & Co. had a return on equity of 143.47% and a net margin of 7.95%.The firm had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same quarter last year, the firm posted $1.38 EPS. On average, sell-side analysts expect that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, December 11th. Investors of record on Thursday, November 20th were paid a dividend of $0.02 per share. This represents a $0.08 annualized dividend and a yield of 1.0%. The ex-dividend date was Thursday, November 20th. Organon & Co.’s dividend payout ratio is presently 4.17%.

Analyst Ratings Changes

A number of brokerages recently issued reports on OGN. Morgan Stanley decreased their price objective on shares of Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating for the company in a report on Tuesday, November 11th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Organon & Co. in a research report on Wednesday, October 8th. Barclays initiated coverage on Organon & Co. in a research note on Tuesday, December 9th. They set an “underweight” rating and a $7.50 price target for the company. Wall Street Zen raised Organon & Co. from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Piper Sandler cut Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 target price for the company. in a research report on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Hold rating and four have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average price target of $8.38.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.